Abstract 4278: A composite neoantigen score is more strongly associated with therapeutic response than tumor mutational burden in a cohort of late-stage anti-PD-1-treated melanoma patients

Authors: Charles W. Abbott, Eric Levy, Rachel Marty Pyke, Rena McClory, Sekwon Jang, Richard Chen, Sean Boyle

Published: 2020-09-04

DOI: 10.1158/1538-7445.am2020-4278

Source: Full article